Evidence map›Paper›PMID 42413500›Full record

ArticleCell reports. Medicine2026

A functional antiplatelet nanomotor for tri-modal ablation of acute arterial thrombus.

Haonan Wu, Hongyuan Zhang, Shuting Guo, Fu Yao, Yuting Sun, Yuan Sun, Shenwu Zhang, Yuequan Wang, Cong Luo

Abstract read
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Haonan WuDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Hongyuan ZhangDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Shuting GuoDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Fu YaoDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Yuting SunDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Yuan SunDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Shenwu ZhangDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China; Joint International Research Laboratory of Intelligent Drug Delivery Systems, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
Yuequan WangDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China. Electronic address: wangyuequan@aliyun.com.
Cong LuoDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China; Joint International Research Laboratory of Intelligent Drug Delivery Systems, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China. Electronic address: luocong@syphu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Timely and safe thrombolysis is a priority in the clinical management of acute arterial embolism. However, current drug therapies face the challenge of balancing therapeutic benefits with bleeding risks. Nanomotors emerge as a promising nonpharmaceutical modality for embolism recanalization, yet transient physical-force-driven antithrombotic therapy cannot achieve long-acting treatment, resulting in unsatisfactory therapeutic outcomes. Here, we exploit a functional antiplatelet nanomotor, which is precisely assembled from a photothermal photosensitizer (DiR), a photothermal-activatable nitric oxide (NO) donor (BNN6), and an antiplatelet drug (ticagrelor [TGL]). Under laser irradiation, the nanomotor achieves deep thrombus penetration through vigorous propulsion enabled by efficient NO generation, while on-site TGL release acts synergistically with NO to enhance antiplatelet function. As expected, the clot-piercing antiplatelet nanomotor displays striking thrombolytic effects in two artery embolism rat models. This study advances a photothermal/mechanical/antiplatelet tri-modal thrombolytic modality toward clinical applicability.

Indexed as

Platelet Aggregation InhibitorsThrombosisAnimalsArteriesBlood PlateletsDisease Models, AnimalHumansMaleNitric OxidePhotosensitizing AgentsRatsRats, Sprague-DawleyThrombolytic TherapyNitric OxidePhotosensitizing AgentsPlatelet Aggregation Inhibitorsantiplateletnanomotornitric oxidephotothermal therapytri-modal thrombolysis

Identifiers

PMID42413500
PMCPMC13522756

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.